Manufacturers and providers have “perverse incentives” to set higher drug prices and pick pricier therapies for patients due to Medicare’s current payment structure, and the system isn’t suitable for expensive modern therapies, said Centers for Medicare and Medicaid Services Administrator Seema Verma at the American Hospital Association’s annual meeting in Washington, D.C.
Source: Drug Industry Daily